Risk assessment for biochemical recurren
✍
Thomas Steuber; Andrew J. Vickers; Alexander Haese; Charlotte Becker; Kim Petter
📂
Article
📅
2005
🏛
John Wiley and Sons
🌐
French
⚖ 122 KB
## Abstract Most models to predict biochemical recurrence (BCR) of prostate cancer use pretreatment serum prostate‐specific antigen (PSA), clinical stage and prostate biopsy Gleason grade. We investigated whether human glandular kallikrein 2 (hK2) and free prostate‐specific antigen (fPSA) measured